Parabilis Medicines
MA - CambridgeBiotechnology
Focus: Parabilis Medicines is a Cambridge-based biotech focused on cell-penetrating miniproteins as a novel modality for oncology. The company is early-stage with a single Phase 1/2 program and operates at pre-revenue scale.
Profile data last refreshed 16m ago · AI intelligence enriched 3w ago
Total Funding
$305M
Open Jobs
16-4 this month
Stable — net -4 jobs in 30d
6 added, 10 removed. Backfill posture.
Should You Work at Parabilis Medicines?
AI assessmentStrong opportunity for early-career scientists and development professionals seeking moonshot upside, but unsuitable for those prioritizing near-term stability or revenue-stage diversity.
Why Work Here
- Backing from Regeneron (recent equity stake as of Aug 2026) signals validation and potential for future financing runway.
- Specialized platform technology (cell-penetrating miniproteins) offers differentiation in oncology if it progresses, positioning early joiners as foundational to a novel mechanism.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
FOG-001
CancerClinical Trials (1)
NCT05919264FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/2Help build intelligence for Parabilis Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.